Trial Profile
Oral anticoagulants verses vitamin-K antagonist in patients with atrial fibrillation undergoing elective cardioversion
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Nov 2016
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Thrombosis
- Focus Therapeutic Use
- 25 Nov 2016 New trial record